Camrelizumab plus nab-paclitaxel in platinum-resistant patients with unresectable locally advanced or metastatic urothelial carcinoma: A multicentre, single-arm, phase II study

被引：1
|
作者：
Li, H. [1 ]
Chen, M. [1 ]
Xue, C. [2 ]
Li, L. [1 ]
Hu, A. [1 ]
Yang, W. [1 ]
Zheng, Z. [3 ]
Ni, M. [1 ]
Zhang, L. [1 ]
Zeng, Y. [1 ]
Peng, J. [1 ]
Yao, K. [4 ]
Zhou, F. [4 ]
Liu, Z. [4 ]
An, X. [1 ]
Shi, Y. [1 ]
机构：
[1] Sun Yat sen Univ, Med Oncol, Canc Ctr, Guangzhou, Peoples R China
[2] Sun Yat sen Univ, Med Oncol, Canc Ctr, Guangzhou, Guangdong, Peoples R China
[3] Sun Yat sen Univ, 3 Med Oncol, Affiliated Hosp 1, Guangzhou, Peoples R China
[4] Sun Yat sen Univ, Urol, Canc Ctr, Guangzhou, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷 / 07期
关键词：
D O I：
10.1016/j.annonc.2022.07.1822
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1744P
引用
收藏
页码：S1335 / S1335
页数：1
相关论文
共 50 条
  • [31] Phase II LAPACT Trial of Nab-Paclitaxel Plus Gemcitabine for Patients With Locally Advanced Pancreatic Cancer
    Bekaii-Saab, Tanios
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2018, 16 (03) : 9 - 10
  • [32] Anlotinib plus pemetrexed in patients with platinum-resistant ovarian cancer: A single-arm, open-label, phase II study
    Chen, J.
    Wei, W.
    Zheng, L.
    Li, H.
    Feng, Y.
    Wan, T.
    Huang, Q.
    Liu, G.
    Tu, H.
    Qiu, J.
    Jiang, X.
    Xiong, Y.
    Zheng, M.
    Li, J.
    Huang, H.
    Song, L.
    Liu, J.
    Zhang, Y.
    ANNALS OF ONCOLOGY, 2021, 32 : S734 - S734
  • [33] Results of a phase II study of single-agent nab-paclitaxel in platinum-refractory second-line metastatic urothelial carcinoma (UC)
    Sridhar, S. S.
    Canil, C. M.
    Mukherjee, S. D.
    Winquist, E.
    Elser, C.
    Eisen, A.
    Reaume, M. N.
    Zhang, L.
    Ko, Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (07)
  • [34] Results of a single-arm pilot study of 32P microparticles in unresectable locally advanced pancreatic adenocarcinoma with gemcitabine/nab-paclitaxel or FOLFIRINOX chemotherapy
    Ross, P. J.
    Wasan, H. S.
    Croagh, D.
    Nikfarjam, M.
    Nguyen, N.
    Aghmesheh, M.
    Nagrial, A. M.
    Bartholomeusz, D.
    Hendlisz, A.
    Ajithkumar, T.
    Iwuji, C.
    Wilson, N. E.
    Turner, D. M.
    James, D. C.
    Young, E.
    Harris, M. T.
    ESMO OPEN, 2022, 7 (01)
  • [35] Apatinib plus camrelizumab in patients with advanced cervical cancer: A multicentre, open-label, single-arm, phase II trial
    Huang, X.
    Shen, J.
    Xiong, Y.
    Wang, Y.
    Cao, X.
    He, M.
    Zou, G.
    Deng, Y.
    Wang, X.
    Lan, C.
    GYNECOLOGIC ONCOLOGY, 2020, 159 : 43 - 43
  • [36] A single-arm phase II study of nab-paclitaxel for patients with chemorefractory non-small cell lung cancer
    Hisashi Tanaka
    Kageaki Taima
    Takeshi Morimoto
    Yoshihito Tanaka
    Masamichi Itoga
    Kunihiko Nakamura
    Akihito Hayashi
    Mika Kumagai
    Hideo Yasugahira
    Megumi Mikuniya
    Koichi Okudera
    Shingo Takanashi
    Sadatomo Tasaka
    BMC Cancer, 17
  • [37] Single-Arm Phase II Study of Nab-Paclitaxel for Patients with Chemorefractory Non-Small Cell Lung Cancer
    Tanaka, Hisashi
    Taima, Kageaki
    Morimoto, Takeshi
    Tanaka, Yoshihito
    Itoga, Masamichi
    Nakamura, Kunihiko
    Hayashi, Akihito
    Kumagai, Mika
    Yasugahira, Hideo
    Mikuniya, Megumi
    Okudera, Koichi
    Takanashi, Shingo
    Tasaka, Sadatomo
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S922 - S922
  • [38] Nab-paclitaxel and cisplatin-based concurrent chemoradiotherapy for locally advanced cervical cancer: A prospective, single-arm phase II clinical trial
    Li, Mingyi
    Qin, Qinghua
    Zhang, Yiqian
    Wu, Qiuyan
    Li, Zhouyu
    Yang, Xinglong
    Cai, Zhantuo
    GYNECOLOGIC ONCOLOGY, 2023, 176 : S72 - S72
  • [39] A single-arm phase II study of nab-paclitaxel for patients with chemorefractory non-small cell lung cancer
    Tanaka, Hisashi
    Taima, Kageaki
    Morimoto, Takeshi
    Tanaka, Yoshihito
    Itoga, Masamichi
    Nakamura, Kunihiko
    Hayashi, Akihito
    Kumagai, Mika
    Yasugahira, Hideo
    Mikuniya, Megumi
    Okudera, Koichi
    Takanashi, Shingo
    Tasaka, Sadatomo
    BMC CANCER, 2017, 17
  • [40] Famitinib with Camrelizumab and Nab-Paclitaxel for Advanced Immunomodulatory Triple-Negative Breast Cancer (FUTURE-C-Plus): An Open-Label, Single-Arm, Phase II Trial
    Chen, Li
    Jiang, Yi-Zhou
    Wu, Song-Yang
    Wu, Jiong
    Di, Gen -Hong
    Liu, Guang-Yu
    Yu, Ke-Da
    Fan, Lei
    Li, Jun-Jie
    Hou, Yi-Feng
    Hu, Zhen
    Chen, Can-Ming
    Huang, Xiao-Yan
    Cao, A-Yong
    Hu, Xin
    Zhao, Shen
    Ma, Xiao-Yan
    Xu, Ying
    Sun, Xiang-Jie
    Chai, Wen -Jun
    Guo, Xiaomao
    Chen, Xizi
    Xu, Yanhui
    Zhu, Xiao-Yu
    Zou, Jian-Jun
    Yang, Wen-Tao
    Wang, Zhong-Hua
    Shao, Zhi-Ming
    CLINICAL CANCER RESEARCH, 2022, 28 (13) : 2807 - 2817
12345